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Abstract  
  Although viruses are the major pathogen that causes upper respiratory tract infection 
(URTI) and acute bronchitis, antibiotics have been prescribed. This was a prospective 
observational study in influenza epidemics that enrolled adult outpatients who visited a 
hospital with respiratory tract infection symptoms. In this study, we evaluated the 
usefulness of FilmArray respiratory panel (RP). Fifty patients were enrolled. FilmArray 
RP detected the pathogens in 28 patients. The common pathogens were influenza virus 
(n=14), respiratory syncytial virus (n=6), and human rhinovirus (n=6). Of the 14 patients 
with influenza virus, 6 were negative for the antigen test. The physicians diagnosed and 
treated the patients without the result of FilmArray in this study. Of the patients with 
positive FilmArray RP, 9 were treated with antibiotics; however, bacteria were detected 
in only 3 patients. By implementing FilmArray RP, URTI and acute bronchitis would be 
precisely diagnosed, and inappropriate use of antibiotics can be reduced.  
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Introduction 
  Acute respiratory tract infection (ARTI) is one of the major infectious diseases that 
may occur at any age and accounts for 3.5 million deaths worldwide.[1] ARTIs are 
classified as acute upper respiratory tract infection (URTI), acute bronchitis, or 
pneumonia. Diagnosis of ARTI except pneumonia is largely based on clinical signs and 
symptoms, because viruses, the most commonly causative pathogens of URTI and acute 
bronchitis, are difficult to detect. However, antibiotics have been prescribed in many 
patients with URTI or acute bronchitis.[2–4] Inappropriate prescription of antibiotics 
promotes antibiotic resistance. Therefore, these viruses should be detected. 
  These viruses could be detected using rapid antigen determination tests; however, 
their sensitivity was relatively low, e.g., the pooled sensitivity of influenza antigen test 
in adults and children with influenza-like illness was 62.3%.[5] To improve the 
sensitivity in detecting the viruses, the nucleic acid amplification test (NAAT) can be 
used. The NAAT has been developed for various viruses[6] and could detect multiple 
targets.[7] Despite these advantages, the use of NAAT has been infrequent because of 
its complicated procedures and difficulty in performing at community hospitals.  
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  In the past few years, several fully automated platforms for NAAT were developed. 
These platforms can be performed simply, provide rapid results, and are used as an 
assay for multiple organisms from a single sample. In this study, one of the fully 
automated platforms, the FilmArray® Respiratory panel (RP), was evaluated. 
FilmArray® RP targets 20 pathogens, including 17 viruses and subtypes and 3 bacteria, 




Material and methods 
Study design 
 A prospective observational study was conducted between January 15 and April 5, 2016, 
in Nagasaki University Hospital and Nagasaki Genbaku Hospital. We enrolled adult 
outpatients who visited the Department of Respiratory Medicine and the Japanese Red 
Cross Nagasaki Genbaku Hospital with respiratory tract infection symptoms such as 
cough, sputum, sore throat, nasal mucus, headache, dyspnea, or hypoxemia. Based on the 
physician’s discretion, chest X-ray and microorganism tests, such as gram stain, culture, 
and influenza antigen test, were performed at the Japanese Red Cross Nagasaki Genbaku 
Hospital. Informed consent and nasopharyngeal swabs for FilmArray RP were obtained 
from all patients. The FilmArray RP analysis was performed at Nagasaki University 
Hospital; however, the results were not reported to the physicians. 
 
Diagnostic criteria 
 The physicians determined the clinical diagnosis without the FilmArray RP results. 
Patients with abnormal shadow in the chest X-ray were diagnosed with pneumonia. The 
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classification of URTI and acute bronchitis were determined based on the clinical history 
and findings of the two physicians, who are certified board members of the Japanese 
Respiratory Society. 
 
Influenza antigen test 
  Influenza antigen test was performed at the Japanese Red Cross Nagasaki Genbaku 
Hospital. In most cases, BD Veritor System™ for rapid detection of Flu A+B (Becton, 
Dickinson and Company, New Jersey, USA) was performed as recommended by the 
manufacturer. ImmunoAce Flu (TAUNS Laboratories, Inc., Sizuoka, Japan) was 
performed as recommended by the manufacturer for some patients who visited the 
hospital after consultation hours. 
 
FilmArray RP 
  FilmArray RP was supplied by the SYSMEX bioMérieux Co., Ltd. (Tokyo, Japan). It 
includes assays that detect Adenovirus; Coronavirus (229E, HKU1, OC43 and NL63); 
Human metapneumovirus; Human rhinovirus; enterovirus; Influenza A with specific 
 8
detection of subtypes H1, H1-2009, and H3; Influenza B, Parainfluenza types 1 to 4; 
Respiratory syncytial virus; Chlamydophila pneumoniae; Mycoplasma pneumoniae; and 
Bordetella pertussis. Testing was performed at Nagasaki University Hospital as 
recommended by the manufacturer. 
 
2.5. Quantitative reverse transcriptase polymerase transcription assay (qRT-PCR) 
 In two samples, FilmArray RP detected only one gene (FluA-pan2), and their results 
were “equivocal.” In these samples, further genetic analysis using the qRT-PCR was 
performed as previously reported[8], because there was a possibility of a false positive or 
negative for Influenza virus A. A one-step qRT-PCR was performed using LightCycler 
480 RNA Master Hydroas.[8] RT-PCR was performed at 63°C for 3 min and 95°C for 30 
s, followed by 45 cycles at 95°C for 10 s and 58°C for 30 s. Standard curves were drawn 
from serial dilutions of viral RNA standards. 
 
Ethics 
  This study was approved by the ethics committee of Nagasaki University Hospital 
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(approval number, 15122108) and the Japanese Red Cross Nagasaki Genbaku Hospital 




 A statistical software package (StatMate V; ATMS Co., Ltd., Tokyo, Japan) was used for 
all the statistical comparisons, which were all two-tailed unpaired and tests of significance. 
The statistical significant α-level was set as ≤0.05. The chi-square or Fisher’s exact test 






 During the study period, a total of 50 patients (22 men and 28 women) with respiratory 
tract symptoms were evaluated. Patient characteristics were shown in Table 1. The mean, 
maximum, and minimum age of the patients were 63.1 ± 20.0, 89, and 24 years, 
respectively. Among the study patients, 29 (58%) had underlying diseases: bronchial 
asthma (10, 20%); COPD (5, 10%); hypertension (4, 8%); Bronchiectasis (3, 6%); 
Diabetes mellitus (3, 6%); other respiratory diseases (4, 8%); and other diseases (3, 6%). 
Common symptoms were fever (74%), cough (74%), sputum (48%), and nasal mucus 
(46%). In 23 patients (46%), abnormal respiratory sounds were auscultated. The most 
common microbiology test in patients was influenza antigen test (41, 82%). The positive 
rate of the influenza antigen test was 22.0% (n=9). Sputum culture was conducted in 18 
patients; 12 of them had positive results. The most common bacteria isolated was 




















Table 1. Patient characteristics 
Age 63.1 ± 20.0 
Sex (male / female) 22 / 28 
Clinical symptoms 50 (100%) 
  Fever 37 (74%) 
  Cough 37 (74%) 
  Sputum 24 (48%) 
  Nasal mucus 23 (46%) 
  Sore throat 16 (32%) 
  Dyspnea 15 (30%) 
  Headache 12 (24%) 
  Hypoxemia 10 (20%) 
Abnormal respiratory sounds 23 (46%) 
  Coarse crackles 14  
  Wheezes 8  
  Decreased breath sounds 2  
Chest X-ray 26 (52%) 
  Abnormal shadow 21  
Microbiology test   
  Influenza antigen test 41 (82%) 
    positive 9  
  Pneumococcal urinary antigen test 25 (50%) 
    positive 2  
  Legionella urinary antigen test 24 (48%) 
    positive 0  
  Sputum culture 18 (36%) 
    Positive 12  
    Haemophilus influenzae 7  
    Staphylococcus aureus 2  
    Escherichia coli 2  
    Others 5  
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Clinical diagnosis and treatment 
  The clinical diagnosis and treatment were determined by the physicians without the 
FilmArray RP results. A total of 20, 8, and 22 patients had URTI, acute bronchitis, and 
pneumonia, respectively (Table 2). One patient with pneumonia was diagnosed with 
interstitial pneumonia. The treatments used for the patients were also shown in Table 2. 
A total of 27 and 10 patients were treated with antibiotics and anti-influenza agents, 
respectively. Two patients were treated with both antibiotics and anti-influenza agents. 
 
Pathogens detected using FlimArray RP 
  FilmArray RP detected the pathogens in 28 patients (56%), namely, Influenza virus 
(n=14, 28%), Respiratory syncytial virus (n=6, 12%), and Human Rhinovirus (n=6, 12%) 
(Table 3). Two viruses were detected in two patients: Influenza virus and Respiratory 




URTI (n=20) 1 (5.0%) 8 (40.0%) 
Acute bronchitis  (n=8) 5 (62.5%) 1 (12.5%) 
Pneumonia  (n=22) 21 (95.5%) 1 (4.5%) 
URTI, acute upper respiratory tract infection 
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syncytial virus and Influenza virus and Human rhinovirus. When the FilmArray RP results 
were arranged in time series (Fig. 1), Respiratory syncytial virus,  
Human rhinovirus, and Coronavirus were observed during the influenza epidemics (from 
January 17 to February 27). 
  The FilmArray RP results were equivocal in two samples with Influenza virus. These 
samples were investigated using qRT-PCR [8], and Influenza virus A subtype H1 was 
detected in both samples. In the 14 patients positive for Influenza virus in the FilmArray 
RP, six were negative during the influenza antigen test. Of the six patients, two were 
clinically diagnosed with influenza and treated with anti-influenza agents. 
 
 Table 3. Results of FilmArray 
Influenza virus A 14 (28%) 
  A H1-2009 11  
  No subtype 1  
  Equivocal 2  
Respiratory syncytial virus 6 (12%) 
Human Rhinovirus 6 (12%) 
Coronavirus 2 (4%) 
  229E 2  
Human Metapneumovirus 2 (4%) 




Relationship between diagnosis and FilmArray RP 
  Figure 2 shows the relationship between the clinical diagnosis and FilmArray RP. In 
patients with URTI (n=20), 85% were positive in the FilmArray RP and the most common 
pathogen was influenza virus (Fig. 2A). In patients with acute bronchitis (n=8), Influenza 
virus (n=1), Respiratory syncytial virus (n=1), Human rhinovirus (n=1), and Human 
metapneumovirus (n=2) were detected (Fig. 2B). In patients with pneumonia (n=22), 73% 
were negative in the FilmArray RP (Fig. 2C). Patients with URTI were significantly 
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higher than those with pneumonia (85% versus 27%, P < 0.001). 
  Nine of the patients who were positive in the FilmArray RP (21.4%) were treated with 
antibiotics. Of the nine patients, sputum culture and bacteria were conducted and detected 





  In this study, FilmArray RP detected the pathogens in 56% of all adult outpatients. 
The detection rate increased to 85% when limited to the patients with URTI. In the 
previous study on FilmArray RP, Genmark eSensor RVP, Luminex xTAG RVP v1, and 
Luminex Fast Multiplex Assays, the consensus positive rate of pathogens in patients 
with URTI was 80.5%.[9] However, the detection rate decreased to 27% when limited 
to patients with pneumonia in this study. Therefore, FilmArray RP was recommended 
for patients with URTI, but not for those with pneumonia. However, the performance of 
FilmArray RP in patients with pneumonia could be improved using lower respiratory 
specimens, such as bronchoalveolar lavage fluids.[10–12]  
  Influenza virus is the most common pathogen detected in the FilmArray RP. In 14 
patients with Influenza virus in the FilmArray RP, six (42.9%) were negative in the 
influenza antigen test. The sensitivity of influenza antigen test was reported as 
62.3%.[5] Additionally, in the study comparing the FilmArray RP and conventional 
culture, the former identified Influenza viruses in all 24 influenza culture-positive cases, 
with a predictive value of 100%.[13] Accordingly, the result of influenza antigen test in 
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the six patients might be false-negative. A multiplex PCR or loop-mediated isothermal 
amplification was performed to compensate for the low sensitivity of the influenza 
antigen test. However, conventional NAAT have not been commonly used as point of 
care testing (POCT) because their procedures are complicated and included manual 
operation. FilmArray RP is a fully automated platform for NAAT and reports a result 
within an hour. FilmArray RP requires only 2 min hands-on time, while in-house real-
time PCR requires 200 min.[14] The mean turnaround time of FilmArray was 2.1 h as 
compared with the in-house real-time PCR with a mean of 26.5 h (P < 0.001).[15] In 
the previous comparative study on FilmArray RP and in-house real-time PCR, after 
conducting the FilmArray, the mean time to the test result was significantly shorter and 
the percentage of patients with a result in the emergency department was greater than 
those before implementation.[16] Therefore, with its high sensitivity, simplicity, and 
rapidity, FilmArray RP can be used as a POCT in patients with URTI. If FilmArray RP 
was used as a routine test, we could diagnose the illness of four patients, who were 
negative for influenza antigen test and not treated with anti-influenza agents, as 
influenza. 
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  Verigene and GeneXpert were other fully automated platforms to detect respiratory 
pathogens aside from the FilmArray; however, they could only detect fewer pathogens. 
The comparative study on FilmArray RP and Verigene RV+ reported that the sensitivity 
and specificity of FilmArray RP was equivalent to Verigene RV+;[17] however, another 
study reported that the sensitivity of FilmArray RP in detecting Influenza virus was 
higher than that of Verigene.[18] A comparative study on FilmArray RP and GeneXpert 
(Xpert Flu) for the detection of Influenza virus reported that the positive predictive 
value for FilmArray RP was almost the same as that of Xpert Flu (FilmArray RP, 98.3% 
and Xpert Flu, 100%, respectively).[19] Furthermore, a previous study on FilmArray 
RP and GeneXpert (Xpert Flu/RSV XC) for the detection of Influenza virus and 
Respiratory syncytial virus reported that the sensitivity and specificity of FilmArray RP 
were equivalent to those of the Xpert Flu/RSV XC).[20] Since this study revealed that 
many viruses caused ARTI even in influenza epidemics, FilmArray might be more 
useful than Verigene and GeneXpert for the detection of pathogens. 
  We detected Influenza virus, Coronavirus, Human metapneumovirus, Human 
rhinovirus, and Respiratory syncytial virus; however, no antimicrobial agents were 
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available for these pathogens, except for Influenza virus. However, these pathogens 
should be detected. In this study, nine patients positive in the FilmArray RP were treated 
with antibiotics, and only three patients were positive during the sputum culture among 
them. From these results, prescribing antibiotics for six patients might be inappropriate. 
The inappropriate use of antibiotics has become a global concern, because it led to the 
emergence of multidrug-resistant pathogens. Although viruses are the most common 
causative pathogens for ARTI, antibiotics have been commonly prescribed in many 
patients with URTI or acute bronchitis.[2–4] A previous study reported that the mean 
duration of antibiotic use was significantly shorter after implementation of FilmArray 
than that before the implementation.[16] Furthermore, the combination of FilmArray RP 
and serum procalcitonin showed the potential to improve the prescription of 
antibiotics.[21] In this study, FilmArray RP results were not reported to the physicians, 
and its use as a routine test may reduce the inappropriate use of antibiotics. 
  This study has some limitations. First, the samples were obtained from one 
community-hospital in Nagasaki, and this may limit the generalizability of the findings. 
Second, the samples were obtained only in influenza epidemics. The epidemiology of 
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the pathogens detected by FilmArray RP might depend on the season. Third, the actual 
impact of FilmArray RP on ARTI diagnosis was not determined, because the results and 
pre- and post-implementation of FilmArray RP were not reported to the physicians. 
Finally, in qRT-PCR analysis, we could detect only H1 but could not detect 2009 
pandemic. We could not verify whether the one gene (Flu-pan2) detected by FilmArray 
RP in two “equivocal” samples were true positive. 
 
Conclusions 
  This study showed the significance of FilmArray RP in patients with ARTI. By 
implementing this kind of fully automated platforms for NAAT, illnesses can be 
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Fig. 1 Time-Series data of FilmArray RP 
  A prospective observational study was conducted between January 15 and April 5, 
2016. During the influenza epidemics, respiratory syncytial virus, human rhinovirus, and 
coronavirus were detected. 
 
Fig. 2. FilmArray RP results in each clinical diagnosis  
  The clinical diagnosis was determined by the physicians without the FilmArray RP 
results. (A) In patients with acute upper respiratory tract infection, the most common 
pathogen was influenza virus. In two patients, two pathogens were detected: influenza 
virus and respiratory syncytial virus and influenza virus and human Rhinovirus. (B) In 
patients with acute bronchitis, influenza virus (n=1), respiratory syncytial virus (n=2), 
and human metapneumovirus (n=2) were detected in the FilmArray RP. (C) In patients 
with pneumonia, 73% were negative in the FilmArray RP. 
 
